Compare Marqeta Inc (MQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Zoetis Inc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.69B), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 18× Marqeta Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | ZTS | |
|---|---|---|
Market Cap | $1.69B | $30.40B |
Sector | Technology | Health |
52-Week High | $23.88 | $150.61 |
52-Week Low | $15.04 | $71.91 |
Enterprise Value | $1.01B | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to positive net income projected for 2026. Recent news highlights product expansions with Google and partnerships in stablecoin-backed cards and European markets, signaling growth initiatives.
The stock offers potential upside to the $19 consensus price target, supported by earnings momentum and strategic partnerships. Key risks include high valuation multiples, intense competition in fintech, and reliance on continued execution amid moderating growth expectations in the second half of 2026.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
